Physician profile
Sharyn Perrone
NPI 1922598127
$11,652.31
in general payments reported to CMS, 2019-2025
36 companies · $3,531 in 2025
The $3,531 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,940 · 2022: $1,777 · 2023: $1,853 · 2024: $2,551 · 2025: $3,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,294 · Education: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,294.15 |
| Education | $641.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,042.24 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $1,015.83 | 2021-2025 | |
| Genzyme Corporation | $975.01 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $909.49 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $854.30 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Regeneron Healthcare Solutions, INC. | $852.32 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $812.11 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $748.81 | 2021-2025 | Otezla, Enbrel, Otezla |
| Leo Pharma INC. | $636.46 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Pfizer INC. | $613.49 | 2021-2025 | |
| Lilly USA, LLC | $599.15 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $503.57 | 2023-2025 | Sotyktu |
| Journey Medical Corporation | $271.61 | 2022-2025 | |
| Incyte Corporation | $195.11 | 2022-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $170.99 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $162.05 | 2021-2025 | Aklief, Oracea, Twyneo |
| Arcutis Biotherapeutics, INC. | $157.47 | 2023-2025 | Zoryve |
| Organon LLC | $155.70 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $118.69 | 2021-2025 | Cabtreo, Jublia |
| Biofrontera INC. | $107.90 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.57 | 2022-2024 | Spevigo |
| Dermavant Sciences, INC. | $104.49 | 2023-2024 | Vtama |
| Epi Health, LLC | $75.17 | 2021 | |
| Kyowa Kirin, INC. | $74.35 | 2022-2025 | Poteligeo |
| Botanix Sb INC | $60.38 | 2025 | Sofdra |
| Genentech USA, INC. | $54.10 | 2021-2025 | Xolair |
| Almirall LLC | $45.69 | 2021-2024 | Klisyri |
| Mayne Pharma Commercial LLC | $43.90 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $43.07 | 2023 | Evusheld |
| Fresenius Kabi USA, LLC | $25.99 | 2023 | |
| Surgenex LLC | $24.18 | 2025 | Surmatrix, Pellograft, Surgraft |
| Vyne Pharmaceuticals INC. | $23.21 | 2021 | |
| Lnhc, INC | $19.57 | 2025 | Zelsuvmi |
| Dermira, INC. | $17.16 | 2021 | |
| Allergan, INC. | $16.95 | 2022 | |
| Verrica Pharmaceuticals INC. | $14.23 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharyn Perrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.